Playbook
How Mochi Health gets its Google traffic
Mochi-branded searches account for an estimated 96.6% of traffic across its top 100 keywords.
- Estimated monthly US organic traffic
- 79,285
- Estimated ranking keywords
- 8,857
- Estimated brand traffic share, top 100
- 96.6%
- Estimated non-brand top-20 keywords
- 2,127
- Estimated AI citation queries
- 973
- Estimated referring domains
- 2,048
The playbook
Mochi-branded searches supply an estimated 96.6% of the traffic in its top 100 keywords. Outside those searches, written treatment guides dominate: the blog holds an estimated 96.5% of its non-brand top-20 keyword footprint. Start with a detailed answer to one customer decision, then connect it to the relevant service.
Scorecard
These are the current research estimates, not measured visits.
| Metric | Result |
|---|---|
| Estimated monthly US organic traffic | 79,285 |
| Estimated ranking keywords | 8,857 |
| Estimated brand share of top 100 keywords’ traffic | 96.6% |
| Estimated non-brand keywords in the top 20 | 2,127 |
| Estimated searches citing Mochi in Google AI Overviews | 973, including brand searches |
| Estimated referring domains | 2,048 |
| Referring-domain change across the 12-month series | Estimated +1,097 (+124.9%): 878 on November 30, 2025 to 1,975 on October 31, 2026 |
| Exact year-over-year referring-domain change | unknown |
| Domain rank | 46 |
| Previously counted sitemap pages | 926; not recounted here |
Traffic engines
Shares below describe estimated ranking keywords, not visits. Page construction is inferred from the pages read; the publishing process is unknown.
| Section | Page type and how it is made | Estimated non-brand top-20 keywords | Estimated share | Top page | Top keyword |
|---|---|---|---|---|---|
| /blog/ | Written articles in a shared layout; appears written by hand rather than filled from a data table | 2,053 | 96.5% | Orforglipron explainer | foundayo |
| /medications/ | Product template filled with medication details and shared care steps | 21 | 1.0% | Topical cream | niacinamide tretinoin cream |
| /blog-authors/ | Profile template filled with credentials and a written biography | 7 | 0.3% | Myra Ahmad | dr myra ahmad |
| Rest of site | Other pages and subdomains; construction varies | 46 | 2.2% | unknown | unknown |
The Orforglipron article shows publication on April 6, 2026 and an update on September 18, 2026. It pairs an explanation with medication and signup links.
| Other pages read | Visible date | Path to the product |
|---|---|---|
| Dose-change guide | Published November 24, 2025; updated September 18, 2026 | A specific treatment question leads to an eligibility check |
| Treatment comparison | Published August 13, 2025; updated September 18, 2026 | Written comparison links to medication pages and access to care |
| Topical cream | unknown | Price, membership requirement, care steps and a purchase button |
| Myra Ahmad profile | unknown | Credentials, personal experience and article links; signup in the navigation |
Top pages
These 15 URLs come from the 20 highest-traffic non-brand top-20 keyword rows. Traffic sums only those sampled rows per URL, not all traffic to each page; the top keyword is the largest contributor in that sample.
| URL | Section | Top sampled keyword | Estimated monthly searches | Estimated absolute position | Estimated monthly traffic from sampled rows |
|---|---|---|---|---|---|
| what-is-orforglipron-the-new-glp-1-weight-loss-pill-explained | /blog/ | foundayo | 135,000 | 11 | 1,125 |
| when-to-titrate-up-on-your-glp-1-dose-signs-you-re-ready-for-the-next-step | /blog/ | how to know when to increase glp-1 dose | 260 | 2 | 137 |
| new-oral-form-of-mounjaro-mazdutide | /blog/ | does mounjaro come in pill form | 1,000 | 4 | 115 |
| mounjaro-dosing | /blog/ | mounjaro doses | 60,500 | 20 | 87 |
| enclomiphene-side-effects | /blog/ | enclomiphene side effects | 8,100 | 8 | 86 |
| tirzepatide-vs-semaglutide | /blog/ | why is tirzepatide more expensive than semaglutide | 390 | 2 | 67 |
| wegovy-dosage | /blog/ | wegovy doses | 74,000 | 19 | 63 |
| how-to-get-rid-of-sulfur-burps | /blog/ | pepto bismol for sulfur burps | 33,100 | 20 | 62 |
| magnesium-for-weight-loss | /blog/ | magnesium glycinate weight loss | 4,400 | 10 | 61 |
| glp-1-plateau-why-it-happens-and-how-to-break-through-it | /blog/ | glp-1 plateau | 1,000 | 4 | 30 |
| ozempic-dosing-for-weight-loss | /blog/ | ozempic starting dose | 1,900 | 15 | 21 |
| which-additive-is-best-for-you-glp-1-additives-explained-b12-l-carnitine-nad-and-more | /blog/ | tirzepatide l carnitine | 1,000 | 8 | 18 |
| pcos-belly | /blog/ | pcos belly | 14,800 | 16 | 18 |
| peptides-for-weight-loss | /blog/ | what are peptides for weight loss | 6,600 | 19 | 18 |
| aequita-quality-reports | /blog/ | aequita pharmacy | 260 | 4 | 17 |
Search patterns
Search volumes are estimated 12-month monthly averages. Other companies’ drug names remain in the non-brand group because they are not Mochi’s brand.
| Pattern | Example keyword | Estimated monthly searches | Section |
|---|---|---|---|
| New treatment or product name | foundayo | 135,000 | /blog/ |
| When to change treatment | how to know when to increase glp-1 dose | 260 | /blog/ |
| Product dosage | mounjaro doses; wegovy doses | 60,500; 74,000 | /blog/ |
| Product side effects | enclomiphene side effects | 8,100 | /blog/ |
| Why one option costs more | why is tirzepatide more expensive than semaglutide | 390 | /blog/ |
| Alternative product format | does mounjaro come in pill form | 1,000 | /blog/ |
| Solve a specific problem | how to get rid of sulfur burps instantly | 9,900 | /blog/ |
| Product ingredients | niacinamide tretinoin cream | 40 | /medications/ |
Foundayo’s monthly estimates rose from 480 in March 2026 to 246,000 in April and stayed elevated through September: a demand shift, not a lone spike. The larger dosage terms also showed sustained demand across the months.
Link magnets
Of 50 linking domains sampled in descending domain-rank order, 42 remain after excluding redirects, app listings, discovery/search pages and user profiles. Counts describe this sample, not the entire backlink profile.
| Page type | What it is | Sampled linking domains | Examples |
|---|---|---|---|
| Homepage | Company coverage, directories and podcast links | 21 | Business Insider, Everyday Health |
| Policy pages | Candidate privacy notice and refunds | 5 | Jobgether, Himalayas, startup.jobs, Goinhouse, BBB |
| Expert profiles and about page | Sources linked by name in health coverage | 4 | Cosmopolitan, SingleCare, two UNIAN domains |
| Medication page | Compounded tirzepatide landing page | 4 | Digital Trends contributor content, Complex, UGA-hosted and CUNY-hosted pages |
| Old blog URLs | Links to earlier article addresses from low-quality pages; not editorial coverage | 4 | Not listed |
| Fulfillment update | One company update referenced by news reposts | 2 | netzender.com, nachedeu.com |
| Eligibility page | Signup destination | 2 | A hosted review page and a Castos podcast episode |
Expert pages are a repeatable link destination. Medication links include contributor content, and the old-blog links are not editorial; neither group proves independent endorsement or explains ranking performance.
Moves to copy
| Move | Evidence at Mochi | Smaller-site version | First page to build |
|---|---|---|---|
| Answer a narrow decision | The dose-change guide ranks at estimated position 2 for its leading question, contributing an estimated 137 monthly visits in the sample | Write one expert-led answer to a recurring customer decision. Explain the criteria and link to the relevant service | “When to upgrade from [basic option] to [advanced option]” |
| Explain price differences | The treatment comparison ranks at estimated position 2 for a cost question, contributing an estimated 67 monthly visits | Compare two real options on price, tradeoffs and fit. Explain the reasons behind the price gap | “Why [option A] costs more than [option B]” |
| Cover a new category development | The Foundayo explainer contributes an estimated 1,125 monthly visits across its two sampled keywords | Publish one useful explainer when a relevant product or standard changes. Update the same page as facts change | “What [new product] means for [customer type]” |
| Make expertise easy to cite | Four sampled domains link to expert profiles or the about page | Give a real specialist a page with credentials, experience and their articles. Use that page when contributing expert commentary | “[Expert name]: experience and published work” |
What won’t copy
| Advantage | Why it does not transfer with a page template |
|---|---|
| Existing brand demand | Mochi-containing terms account for an estimated 73,011 of 75,585 monthly visits across the top 100 keyword rows. Login and support searches include existing customers |
| Established links | An estimated 2,048 domains link to Mochi. The sample includes links first seen in 2022; a new site cannot reproduce that history by publishing more pages |
| Access to specialists | Named experts and treatment experience support the content and media citations. A byline alone does not create that expertise |
| A fast-moving treatment market | Foundayo demand changed sharply during 2026. Its traffic opportunity does not imply similar demand for an unrelated startup |
| Ranking does not prove acquisition | The estimated 973 AI Overview citation queries and organic rankings do not reveal paid memberships. Conversion rates are unknown |
Method
Data from OpenSEO (DataForSEO estimates, US market, English), researched on 2026-11-18, with direct reading of Mochi pages. “Non-brand” excludes keywords containing “mochi”; it retains drug, person and pharmacy names, so it is not a measure of wholly unfamiliar prospects. The bare “mochi” query is ambiguous but included in the brand calculation. Page traffic is summed across 20 sampled organic keyword rows; AI citations are counted separately. Link counts use one result per source domain and are not a census of editorial endorsements.